2361497-72-3

CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes[1][2].

[1] Mach M, et al. Discovery and development of CPL207280 as new GPR40/FFA1 agonist. Eur J Med Chem. 2021;226:113810. DOI:10.1016/j.ejmech.2021.113810
[2] Bazydlo-Guzenda K, et al. CPL207280-a novel GPR40/FFA1-specific agonist shows a favorable safety profile and exerts anti-diabetic effects in type 2 diabetic animals[J]. Molecular Pharmacology, 2021.